Zhang Mengying, Zhang Gaochao, Xu Fangfang, Liu Mengyuan, Dong Xifeng, Qi Weiwei, Wang Huaquan
Department of Hematology, Tianjin Medical University General Hospital, Tianjin, People's Republic of China.
Department of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing, People's Republic of China.
Glob Med Genet. 2023 Jul 28;10(3):194-198. doi: 10.1055/s-0043-1771456. eCollection 2023 Sep.
Our objective was to investigate the concentration of plasma thrombopoietin (TPO) in patients with aplastic anemia (AA) and myelodysplastic syndrome (MDS), as well as its relationship with patients' responses to recombined human TPO (rhTPO) therapy. We detected the concentration of plasma TPO in 31 patients with AA, 27 patients with MDS, and 11 normal controls using enzyme-linked immunosorbent assay. The median concentration of plasma TPO in patients with AA, MDS, and controls was (841.08 ± 768.64), (212.41 ± 338.93), and (35.09 ± 18.21) pg/mL, respectively. The TPO concentration in patients with AA and MDS was significantly higher than that in controls ( < 0.05). The median platelet (PLT) counts were (184 ± 34) ×10 /L in the control group and (24 ± 19) ×10 /L and (80 ± 71) ×10 /L in AA and MDS patients, respectively. Negative correlations were found between plasma TPO concentration and PLT counts as well as megakaryocytes in bone marrow ( < 0.05). In AA patients treated with rhTPO, a negative correlation was observed between increased PLT counts and pretreatment TPO levels ( < 0.05). Plasma TPO concentration in AA and MDS was significantly higher than that in normal controls. Plasma TPO was negatively correlated with peripheral blood PLT counts and bone marrow megakaryocyte counts. The pretreatment TPO level may serve as a prognostic indicator for the therapeutic effect of rhTPO in AA patients.
我们的目的是研究再生障碍性贫血（AA）和骨髓增生异常综合征（MDS）患者血浆血小板生成素（TPO）的浓度，以及其与患者对重组人TPO（rhTPO）治疗反应的关系。我们采用酶联免疫吸附测定法检测了31例AA患者、27例MDS患者和11例正常对照者的血浆TPO浓度。AA患者、MDS患者和对照者的血浆TPO中位浓度分别为（841.08±768.64）、（212.41±338.93）和（35.09±18.21）pg/mL。AA和MDS患者的TPO浓度显著高于对照者（P<0.05）。对照组的中位血小板（PLT）计数为（184±34）×10⁹/L，AA和MDS患者的分别为（24±19）×10⁹/L和（80±71）×10⁹/L。血浆TPO浓度与PLT计数以及骨髓巨核细胞之间呈负相关（P<0.05）。在接受rhTPO治疗的AA患者中，观察到PLT计数的增加与治疗前TPO水平之间呈负相关（P<0.05）。AA和MDS患者的血浆TPO浓度显著高于正常对照者。血浆TPO与外周血PLT计数和骨髓巨核细胞计数呈负相关。治疗前TPO水平可能作为AA患者rhTPO治疗效果的预后指标。
